Paper · 42587090
Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.
Saj F and 1 other. Nat Rev Clin Oncol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma. Papers, record 42587090. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42587090
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41,372,578 | Cholangiocarcinoma 2026: status quo, unmet needs and priorities. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41372578 | PubMed |
| 2 | 39,706,336 | A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. | Ann Oncol | 2025 | https://conductscience.org/library/papers/39706336 | PubMed |
| 4 | 41,850,040 | Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301. | ESMO Open | 2026 | https://conductscience.org/library/papers/41850040 | PubMed |
| 5 | 39,841,128 | Novel clinical trial designs emerging from the molecular reclassification of cancer. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39841128 | PubMed |
| 6 | 42,223,137 | Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/42223137 | PubMed |
| 7 | 32,289,268 | Toward a More Precise Future for Oncology. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32289268 | PubMed |
| 8 | 41,678,089 | Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma. | Invest New Drugs | 2026 | https://conductscience.org/library/papers/41678089 | PubMed |
| 9 | 38,319,896 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319896 | PubMed |
| 10 | 37,075,781 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37075781 | PubMed |
Cited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42587090
GET https://conductscience.org/api/papers/v1/42587090/authors